Mykor Secures £4M to Scale Mycelium Construction, Redefining Sustainable Building
June 1, 2026, 3:37 pm
Mykor secures £4 million funding, totaling £7.5 million. This UK biotech leader converts industrial and agricultural waste into low-carbon construction materials via engineered mycelium. The investment accelerates production, product development, and European expansion. Mykor's platform offers scalable, commercially viable solutions. It meets critical demand for sustainable building, addressing construction's environmental impact and tightening regulations across the UK and Europe. Over £338 million in commercial agreements reflect strong market adoption for their innovative materials.
The construction sector faces immense pressure. It is a major contributor to global carbon emissions. Governments demand greener practices. Developers seek sustainable building materials. Conventional methods prove carbon-intensive. Waste streams also pose environmental challenges. A shift is urgent.
Mykor offers a groundbreaking solution. This UK biotechnology company tackles construction's pressing challenges directly. It engineers new-generation materials. The firm converts industrial and agricultural waste. This process creates low-carbon alternatives. Their technology leverages proprietary mycelium strains. Green chemistry additives enhance performance. Closed-loop biofabrication processes define their approach.
Mykor recently announced significant investment. A £4 million funding round closed successfully. This brought total investment to £7.5 million. Clean Growth Fund led the round. The FSE Group also participated. British Business Bank’s South West Investment Fund contributed. Green Angel Ventures and Innovate UK provided additional support. This capital infusion accelerates Mykor’s mission.
The investment targets several key areas. It supports continued development. It drives commercialization of their biotechnology platform. Funds will expand production capabilities. Product development will advance. Commercial partnerships will strengthen. European market expansion is a core objective. Demand for sustainable construction solutions grows relentlessly.
Mykor's innovative products replace or supplement traditional options. They offer prefabricated wall systems. Cavity wall insulation is another key offering. These biomaterials meet crucial performance standards. Fire safety remains paramount. Durability and acoustic performance are comparable. Affordability is central to their strategy. Mykor ensures large-scale adoption is viable.
The company's approach is unique. It operates as a scalable technology platform. Mykor is not merely a materials manufacturer. Its platform enables integration. Contractors, manufacturers, and partners can adopt biomaterials easily. They fit into existing supply chains. Production facilities require minimal operational changes. This platform-based strategy accelerates market adoption. It spans multiple construction segments.
Mykor’s first commercial product exemplifies this innovation. MykoSIP is a prefabricated partition wall system. It significantly reduces embodied carbon. This system matches conventional alternatives. Thermal and acoustic performance are comparable. Production uses less water. Electricity consumption is also lower. These efficiencies make MykoSIP a compelling choice.
The market urgently needs such solutions. Building regulations across the UK are tightening. European directives also increase pressure. These mandates demand lower-carbon materials. Energy-efficient building systems are crucial. Mykor directly addresses these regulatory requirements. Their timing is opportune.
Mykor’s technology directly impacts construction's environmental footprint. The sector is a major contributor to global emissions. Reducing this impact is vital. Mykor combines biological manufacturing with industrial-scale methods. This synergy creates competitive sustainable alternatives. Performance, safety, and cost considerations remain central.
Commercial success validates Mykor’s vision. The company secured over £338 million in commercial agreements. These agreements span the UK and Europe. They cover a range of construction and development projects. This demonstrates strong market interest. Public and private sector customers seek low-carbon building materials. Mykor delivers.
Mykor was founded in 2021. The vision was clear. Decarbonizing construction must not sacrifice practicality. Cost-effectiveness is essential. Performance cannot be compromised. The challenge was never just inventing a biomaterial. It was about industrial-scale manufacturing. It meant integrating systems into real supply chains. Mykor has achieved this integration.
The company utilizes agricultural and industrial byproducts as feedstocks. This reduces waste. It also creates commercially viable materials. This circular economy approach is inherently sustainable. It minimizes environmental impact. It maximizes resource efficiency.
The recent funding round strengthens Mykor’s position. It secures resources for aggressive growth. The company is already active in construction projects. Expansion into additional markets is imminent. Mykor is poised for significant impact. Its technology offers a clear path forward. It advances sustainable construction practices globally.
Mykor embodies a new era for building. It merges biotechnology with construction needs. It delivers materials that are good for the planet. They are also good for business. The company sets a precedent. Sustainable construction is achievable. It is scalable. It is commercially viable. The future of the built environment looks greener thanks to Mykor.
The construction sector faces immense pressure. It is a major contributor to global carbon emissions. Governments demand greener practices. Developers seek sustainable building materials. Conventional methods prove carbon-intensive. Waste streams also pose environmental challenges. A shift is urgent.
Mykor offers a groundbreaking solution. This UK biotechnology company tackles construction's pressing challenges directly. It engineers new-generation materials. The firm converts industrial and agricultural waste. This process creates low-carbon alternatives. Their technology leverages proprietary mycelium strains. Green chemistry additives enhance performance. Closed-loop biofabrication processes define their approach.
Mykor recently announced significant investment. A £4 million funding round closed successfully. This brought total investment to £7.5 million. Clean Growth Fund led the round. The FSE Group also participated. British Business Bank’s South West Investment Fund contributed. Green Angel Ventures and Innovate UK provided additional support. This capital infusion accelerates Mykor’s mission.
The investment targets several key areas. It supports continued development. It drives commercialization of their biotechnology platform. Funds will expand production capabilities. Product development will advance. Commercial partnerships will strengthen. European market expansion is a core objective. Demand for sustainable construction solutions grows relentlessly.
Mykor's innovative products replace or supplement traditional options. They offer prefabricated wall systems. Cavity wall insulation is another key offering. These biomaterials meet crucial performance standards. Fire safety remains paramount. Durability and acoustic performance are comparable. Affordability is central to their strategy. Mykor ensures large-scale adoption is viable.
The company's approach is unique. It operates as a scalable technology platform. Mykor is not merely a materials manufacturer. Its platform enables integration. Contractors, manufacturers, and partners can adopt biomaterials easily. They fit into existing supply chains. Production facilities require minimal operational changes. This platform-based strategy accelerates market adoption. It spans multiple construction segments.
Mykor’s first commercial product exemplifies this innovation. MykoSIP is a prefabricated partition wall system. It significantly reduces embodied carbon. This system matches conventional alternatives. Thermal and acoustic performance are comparable. Production uses less water. Electricity consumption is also lower. These efficiencies make MykoSIP a compelling choice.
The market urgently needs such solutions. Building regulations across the UK are tightening. European directives also increase pressure. These mandates demand lower-carbon materials. Energy-efficient building systems are crucial. Mykor directly addresses these regulatory requirements. Their timing is opportune.
Mykor’s technology directly impacts construction's environmental footprint. The sector is a major contributor to global emissions. Reducing this impact is vital. Mykor combines biological manufacturing with industrial-scale methods. This synergy creates competitive sustainable alternatives. Performance, safety, and cost considerations remain central.
Commercial success validates Mykor’s vision. The company secured over £338 million in commercial agreements. These agreements span the UK and Europe. They cover a range of construction and development projects. This demonstrates strong market interest. Public and private sector customers seek low-carbon building materials. Mykor delivers.
Mykor was founded in 2021. The vision was clear. Decarbonizing construction must not sacrifice practicality. Cost-effectiveness is essential. Performance cannot be compromised. The challenge was never just inventing a biomaterial. It was about industrial-scale manufacturing. It meant integrating systems into real supply chains. Mykor has achieved this integration.
The company utilizes agricultural and industrial byproducts as feedstocks. This reduces waste. It also creates commercially viable materials. This circular economy approach is inherently sustainable. It minimizes environmental impact. It maximizes resource efficiency.
The recent funding round strengthens Mykor’s position. It secures resources for aggressive growth. The company is already active in construction projects. Expansion into additional markets is imminent. Mykor is poised for significant impact. Its technology offers a clear path forward. It advances sustainable construction practices globally.
Mykor embodies a new era for building. It merges biotechnology with construction needs. It delivers materials that are good for the planet. They are also good for business. The company sets a precedent. Sustainable construction is achievable. It is scalable. It is commercially viable. The future of the built environment looks greener thanks to Mykor.